Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06891885 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
A Phase 1 study of Retinitis Pigmentosa, sponsored by Sumitomo Pharma America.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06891885 is a Phase 1 study of Retinitis Pigmentosa that is actively recruiting participants, run by Sumitomo Pharma America. The registered enrollment target is 12 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06891885, a Phase 1 study of Retinitis Pigmentosa, is actively recruiting participants, sponsored by Sumitomo Pharma America.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.
Conditions Studied
Interventions
- DRUG DSP-3077 Retinal Sheet Cohort 1
- DRUG DSP-3077 Retinal Sheet Cohort 2
- DRUG DSP-3077 Retinal Sheet Cohort 3
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2032-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06891885
The ClinicalTrials.gov registry entry for NCT06891885 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (95% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 3 interventions - of which DSP-3077 Retinal Sheet Cohort 1 is the first listed.
NCT06891885 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06891885 about?
NCT06891885 is a clinical study titled "A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa". The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participan...
What is the current status of trial NCT06891885?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-10-23. Estimated completion is 2032-10-31.
What conditions does trial NCT06891885 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT06891885?
The interventions under investigation include: DSP-3077 Retinal Sheet Cohort 1 (DRUG), DSP-3077 Retinal Sheet Cohort 2 (DRUG), DSP-3077 Retinal Sheet Cohort 3 (DRUG).
Who is sponsoring clinical trial NCT06891885?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06891885 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
BS01 in Patients With Retinitis Pigmentosa
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC for the Treatment of RP
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.